KPV Protocol: Dosing, Timing & Cycle Guide
What KPV Does KPV (Lys-Pro-Val) is a tripeptide consisting of just three amino acids — the smallest bioactive fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino-acid hormone with potent anti-inflammatory properties, but it al
What KPV Does
KPV (Lys-Pro-Val) is a tripeptide consisting of just three amino acids — the smallest bioactive fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino-acid hormone with potent anti-inflammatory properties, but it also causes skin darkening through melanocortin receptor activation. KPV preserves the anti-inflammatory activity while eliminating the tanning effect.
The mechanisms that matter for your protocol:
- NF-kB inhibition — KPV directly inhibits nuclear factor kappa B, the master transcription factor that drives inflammatory gene expression. NF-kB is the central switch for TNF-alpha, IL-6, IL-1beta, and other pro-inflammatory cytokines
- Cytokine suppression — reduces production of TNF-alpha, IL-6, IL-1beta, and other inflammatory mediators
- Intestinal epithelial protection — KPV enters colonic epithelial cells and reduces inflammatory signaling at the tissue level, protecting the gut barrier
- Antimicrobial activity — KPV has direct antimicrobial properties against certain pathogenic bacteria, including Staphylococcus aureus and Candida albicans
- Immune cell modulation — reduces inflammatory activation of macrophages and dendritic cells without broad immunosuppression
Why KPV Matters
Most anti-inflammatory interventions are either too broad (corticosteroids suppress the entire immune system) or too narrow (biologics target a single cytokine). KPV operates at the NF-kB level — upstream of individual cytokines but downstream of immune activation. This means it reduces pathological inflammation without eliminating the immune system’s ability to respond to real threats.
The Gut Health Application
Inflammatory Bowel Disease Research
KPV’s most compelling research is in intestinal inflammation. Key findings:
Dalmasso G et al. (2008, PLoS ONE):
- Oral KPV significantly reduced colitis severity in DSS-induced and T-cell transfer colitis models
- KPV was transported into colonic epithelial cells via the PepT1 transporter
- Once inside epithelial cells, KPV directly inhibited NF-kB activation
- Effect was dose-dependent and comparable to established anti-inflammatory drugs
Laroui H et al. (2010, Gastroenterology):
- KPV-loaded nanoparticles delivered orally showed enhanced colonic targeting
- Significantly reduced colitis markers with lower systemic exposure
- Demonstrated feasibility of targeted oral KPV delivery
KPV vs BPC-157 for Gut Issues
Both peptides are used for gut health, but through different mechanisms:
| Feature | KPV | BPC-157 |
|---|---|---|
| Primary mechanism | Anti-inflammatory (NF-kB inhibition) | Tissue repair (angiogenesis, GHR upregulation) |
| Best for | Active inflammation (IBD, colitis) | Tissue damage (leaky gut, ulcers, NSAID injury) |
| Oral viable? | Yes (PepT1 transporter) | Yes (gastric acid stable) |
| Speed | Days (anti-inflammatory effect) | Weeks (tissue remodeling) |
| Systemic inflammation | Yes (NF-kB is systemic) | Limited systemic anti-inflammatory effect |
| Gut barrier repair | Indirect (reduces damage from inflammation) | Direct (promotes epithelial healing) |
| Cost | $60–120/mo | $40–80/mo |
Combined protocol: For inflammatory gut conditions with barrier damage (common in IBD), some practitioners use both — KPV to suppress inflammation and BPC-157 to repair damaged tissue.
Dosing Protocol
Injectable Protocol (Systemic)
| Parameter | Detail |
|---|---|
| Dose | 200–500 mcg/day |
| Starting dose | 200 mcg once daily |
| Frequency | Once or twice daily |
| Cycle | 4–8 weeks on, 4 weeks off |
| Injection site | Subcutaneous (abdomen) |
Oral Protocol (Gut-Targeted)
| Parameter | Detail |
|---|---|
| Dose | 200–500 mcg/day |
| Starting dose | 200 mcg once daily |
| Timing | On empty stomach (enhances PepT1 transport) |
| Cycle | 4–8 weeks on, 4 weeks off |
Oral administration is preferred for gut-specific conditions because KPV reaches the intestinal mucosa directly and is transported into epithelial cells via PepT1.
By Condition
| Condition | Route | Dose | Duration |
|---|---|---|---|
| IBD / Colitis | Oral | 300–500 mcg/day | 6–8 weeks |
| General gut inflammation | Oral | 200–300 mcg/day | 4–6 weeks |
| Systemic inflammation | SC injection | 300–500 mcg/day | 4–8 weeks |
| Skin inflammation | SC injection | 200–400 mcg/day | 4–6 weeks |
Beyond the Gut
Systemic Anti-Inflammatory
KPV’s NF-kB inhibition is not gut-specific — it works in any tissue where NF-kB drives inflammation:
- Joint inflammation — NF-kB is a key driver of osteoarthritis and rheumatoid arthritis pathology
- Skin inflammation — KPV has been studied for contact dermatitis and allergic skin reactions
- Neuroinflammation — NF-kB drives neuroinflammatory cascades implicated in cognitive decline
- Post-injury inflammation — systemic inflammation after surgery or significant tissue injury
Antimicrobial Properties
KPV demonstrates direct antimicrobial activity against:
- Staphylococcus aureus (including some resistant strains)
- Candida albicans
This dual anti-inflammatory + antimicrobial action is particularly relevant for gut conditions where inflammation and microbial imbalance coexist.
Safety & Contraindications
Side Effects
KPV has a favorable safety profile in published research:
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection-site reaction | Common | Standard SC reaction |
| Mild GI changes | Occasional | Usually with oral dosing, transient |
| Headache | Rare | Usually first few days only |
What KPV Does NOT Cause
- No skin darkening (unlike full-length alpha-MSH or Melanotan)
- No appetite changes (unlike melanocortin agonists)
- No immunosuppression (unlike corticosteroids)
- No hormonal effects (unlike many peptides)
Contraindications
- Active infection requiring immune response — while KPV is not immunosuppressive, reducing NF-kB during acute infection could theoretically impair pathogen clearance
- Concurrent immunosuppressant therapy — additive anti-inflammatory effects may be excessive
- Pregnancy/breastfeeding — no safety data
- Under 18 — no pediatric data
Blood Work
| Marker | When | Why |
|---|---|---|
| CRP (C-Reactive Protein) | Baseline + 6 weeks | Confirm anti-inflammatory effect |
| ESR | Baseline + 6 weeks | Secondary inflammation marker |
| CBC | Baseline | General immune baseline |
| CMP | Baseline | Liver and kidney function |
For IBD patients: calprotectin (fecal) at baseline and 8 weeks is the gold standard for tracking intestinal inflammation.
Research & Citations
Gut inflammation: Dalmasso G et al., “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation,” PLoS ONE (2008). Demonstrated oral KPV’s anti-colitic effects and PepT1-mediated transport mechanism.
Nanoparticle delivery: Laroui H et al., “Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model,” Gastroenterology (2010). Advanced delivery system for targeted KPV delivery to colonic tissue.
Anti-inflammatory mechanism: Brzoska T et al., “Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects,” Endocrine Reviews (2008). Comprehensive review of alpha-MSH-derived peptides including KPV.
Antimicrobial activity: Cutuli M et al., “Antimicrobial effects of alpha-MSH peptides,” Journal of Leukocyte Biology (2000). Demonstrated KPV’s direct antimicrobial properties.
- BPC-157 Protocol — complementary gut healing peptide
- Thymosin Alpha-1 Protocol — immune modulation
- Peptide Safety Guide — injection technique, storage, general safety
- How to Inject Peptides — step-by-step injection guide
- Reconstitution Calculator — dosing math for your vials